Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NR1I3 | Q14994 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835493 | 1.00 | DPP8 (0.39) | DPP8DPP9GHSRAPLNRBDKRB1 | |
| SCHEMBL31730656 | 0.81 | BACE1 (0.41) | GHSRBACE1 | |
| SCHEMBL4513886 | 0.81 | HDAC4 (0.33) | DPP8DPP9APLNRRORC | |
| SCHEMBL306307 | 0.80 | GHSR (0.43) | DPP8DPP9GHSRBACE1EPHX2 | |
| SCHEMBL18614341 | 0.80 | GHSR (0.43) | DPP8DPP9GHSRBACE1EPHX2 | |
| SCHEMBL4837190 | 0.80 | GHSR (0.43) | DPP8DPP9GHSRBACE1EPHX2 | |
| SCHEMBL24781343 | 0.74 | NPC1 (0.32) | GHSRAPLNRBACE1RORC | |
| SCHEMBL28970176 | 0.74 | NPC1 (0.32) | GHSRAPLNRBACE1RORC | |
| SCHEMBL24781183 | 0.74 | NPC1 (0.32) | GHSRAPLNRBACE1RORC | |
| SCHEMBL30060575 | 0.74 | NPC1 (0.32) | GHSRAPLNRBACE1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442692-B2 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-28 | — | — | US | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | DPP8 2509/4885DPP9 3947/4885GHSR 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.